acapatamab + pembrolizumab

Acapatamab + pembrolizumab is an **investigational combination therapy** under clinical development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). **Acapatamab** is a half-life extended bispecific T cell engager (BiTE) antibody construct that targets **prostate specific membrane antigen (PSMA)** on tumor cells and **CD3** on T cells, redirecting T cells to kill PSMA-expressing tumor cells. **Pembrolizumab** is a humanized monoclonal antibody checkpoint inhibitor targeting the **programmed death 1 (PD-1) receptor**, thereby enhancing T-cell mediated antitumor immune responses. This combination aims to enhance antitumor efficacy by simultaneously activating T-cell cytotoxicity and overcoming immune checkpoints inhibiting T-cell function. The combination is being studied in a phase 1 clinical trial for mCRPC patients who are refractory to standard treatments[1][3][5][7].

Other names

PSMA Targeted Therapy (for acapatamab)anti-PD-1 antibody (for pembrolizumab)